Lam Research Corporation vs uniQure N.V. Ordinary Shares — how do they compare? Lam Research Corporation trades at $282.67 (market cap $376.82B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: Lam Research Corporation is far larger — about 254.6× uniQure N.V. Ordinary Shares's market cap, and Lam Research Corporation pays a 0.44% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lam Research Corporation for 61 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| LRCX | QURE | |
|---|---|---|
Market Cap | $376.82B | $1.48B |
Volume | 8,149,593 | 2,488,780 |
Sector | Technology | Health |
52-Week High | $433.33 | $70.59 |
52-Week Low | $139.59 | $9.03 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | $374.97B | $728.62M |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $286.92, down 7.31% in the last session, amid a bearish technical signal. The stock shows strong fundamentals with revenue growth to $18.44B in 2025 and a 31.27% net income margin. Recent quarters have consistently beaten EPS estimates, with Q3 2026 expected at $2.18. Analyst consensus remains strongly bullish with a $375.68 price target, though technical indicators suggest near-term pressure with support at $300.
Outlook: LRCX is positioned to benefit from AI-driven semiconductor equipment demand, with projected revenue growth to $23.2B in 2026. Risks include cyclical industry volatility and execution challenges. The current valuation (P/E 52.28) is high but supported by robust profitability and growth prospects. Institutional sentiment is positive with 78% buy ratings.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →